A2 Biotherapeutics, Inc.

A2 Biotherapeutics, Inc announced the acceptance of six abstracts for presentation at the Society for Immunotherapy of Cancer (SITC) annual meeting on November 8-10, 2024 in Houston. We are especially proud to present safety and biomarker data on the EVEREST-1 (NCT05736731) study as well as an oral presentation highlighting continued progress in enhancing the diversity of patients enrolled in the BASECAMP-1 prescreening trial. A2 Bio will also present progress on our EVEREST-2 trial (NCT06051695), and adaptations to boost potency and preserve selectivity of Tmod™ based cell therapies. For more information on our press release, please visit: https://lnkd.in/gvnFeWsK For more information on our clinical studies, please visit: https://lnkd.in/ge7KqZ8T #SITC #SITC2024 #A2Bio #Tmod #CellTherapy

As September, Ovarian Cancer Awareness Month, comes to a close, it's important to reflect on the work being done to address this challenging disease. At A2 Bio, we're committed to advancing innovative treatments. We are currently testing A2B694 in the EVEREST-2 study (NCT06051695), a potential treatment for ovarian cancer in patients whose tumors express MSLN and have lost HLA-A*02. Our goal is to make a meaningful impact for those affected by this devastating illness. To read more about the EVEREST-2 study, please visit: https://lnkd.in/gmbGrGjP #OvarianCancerAwareness #CellTherapy #A2Bio

Kirstin Liechty, a Senior Director of Clinical Operations at A2 Biotherapeutics, will present at the upcoming CAR-TCR Summit in Boston, MA. As our clinical operations lead executing on our current Phase 1/2 clinical studies, Kirstin will share her insights on "Clinical Operations in the Era of Precision Medicine." For more information on our BASECAMP-1, EVEREST-1, and EVEREST-2 clinical trials, please visit: https://lnkd.in/gdGnHuty #A2Bio #CARTCR #precisionmedicine #HLA #BiologyNews #Oncology

Our paper on a clinical diagnostic to detect human leukocyte antigen (HLA) loss of heterozygosity (LOH) was just published in Nature Precision Oncology! Rapid and routine HLA assessment is critical for current and emerging immunotherapies, and loss of specific HLA alleles in tumor tissue provides a novel therapeutic opportunity that is key to the investigational products at A2 Bio. Our diagnostic partner, Tempus AI, developed an investigational assay for detection of the loss of HLA alleles that is seamlessly integrated into their standard xT CDx. This enables efficient HLA assessment, and identification of patients potentially eligible for our pre-screening study, BASECAMP-1 (NCT04981119) and subsequent therapeutic studies EVEREST-1 (NCT05736731) and EVEREST-2 (NCT06051695). This paper describes the technical details of the clinical diagnostic and demonstrates the biological relevance of HLA-LOH for patients with lung cancer. #precisionmedicine #HLA #BiologyNews #Oncology #A2Bio Below is a link to the article: https://lnkd.in/gZjttYXp

Last week, we hosted our first "Bring Your Kids to Work Day" at our A2 Bio campus in Agoura Hills, CA. It was heartwarming to see 32 kids having so much fun learning about our science and exploring our facilities. Special thanks to our A2 Bio volunteers for making a great work experience for kids, inspiring them to be curious about their future careers and have fun. The kids participated in hands-on science experiments, had the opportunity to tour our labs, and hear from A2 leaders on what inspired them to pursue a career in biotechnology. #A2 Bio #Biotech #CellTherapy #TakeYourKidsToWork

A2 Biotherapeutics is pleased to announce the appointment of Ryan Card as general counsel. Ryan will be responsible for leading the legal function for A2 Bio, a clinical-stage biotechnology company developing first-in-class logic-gated cell therapies for solid tumors, based in Agoura Hills, California. Before joining A2 Bio, Ryan served as executive vice president, general counsel and chief compliance officer of Urovant Sciences until the company’s merger into Sumitomo Pharma America in 2023. In this role, he led Urovant's legal and compliance functions through the successful launch of the company's first commercial product in the United States, GEMTESA® (vibegron). Prior to joining Urovant, Ryan was executive director, senior counsel with Allergan plc, where he worked as chief counsel for the company’s neurology, eye care, and urology business units, which included the company's BOTOX therapeutic franchise. Previously, Ryan was a senior litigation associate with Gibson, Dunn & Crutcher, LLP. He earned a bachelor of science degree from the University of Utah and his law degree from Brigham Young University Law School. #Biotech #OncologyNews #CellTherapy #A2 Bio

A2 Bio celebrated our annual summer picnic last week in beautiful Agoura Hills, CA. It was a wonderful turnout that brought our staff, friends, and family together to share food, ice cream, and games. Special thanks to all who attended for making this such a memorable event. #A2Bio #CellTherapy #Tmod #Biotech #Oncology #Agoura Hills

At A2 Bio, we are working together for a better tomorrow for patients with cancer. To tackle such an ambitious goal, we need the help of a dedicated team of scientists, manufacturers, and industry professionals from diverse backgrounds. Together we can work effectively and efficiently to support patients. A2 Bio is proud to support Pride month and the LGBTQ+ community.  

A2 Bio is proud to announce the launch of its new A2bioclinicaltrials.com website. We've designed the website to provide Patients & Caregivers information on our clinical studies, including infographics to help explain the patient journey. The site also includes a section to support healthcare providers with information on our pre-screening, observational study, BASECAMP-1, to identify participants who might benefit from future Tmod CAR T-cell therapy in our investigational studies. A2 Bio would like to thank the clinical sites, teams, and patients for providing the inspiration and encouragement to launch this new website. Visit our new site: https://lnkd.in/g2JF-ANQ #A2Bio #Tmod #Biotech #CellTherapy #clinicaltrials #innovation #biotechnews #TCells #CarT

A2 Bio is proud to present updates on three ongoing clinical trials in poster presentation at ASCO 2024. The poster presentations are scheduled on Saturday, June 1st from 9:00 - 12:00 pm CT. For more information on our clinical trials, please go to https://lnkd.in/ge7KqZ8T To view the press release: https://lnkd.in/g6RRrgig #BiologyNews #Oncology #A2Bio #Tmod #ASCO24